(Q39414806)

11 September 2017

title

Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial (English)

1 reference

11 September 2017

main subject

phase I clinical trial

0 references

1 reference

Lori Berk

1

1 reference

11 September 2017

Monica M Mita

2

1 reference

11 September 2017

Jeff Kreisberg

3

1 reference

11 September 2017

Camille L Bedrosian

4

1 reference

11 September 2017

Anthony W Tolcher

5

1 reference

11 September 2017

Tim Clackson

6

1 reference

11 September 2017

Victor M Rivera

7

1 reference

11 September 2017

publication date

10 January 2012

1 reference

Cancer Chemotherapy and Pharmacology

11 September 2017

published in

1 reference

11 September 2017

volume

69

1 reference

11 September 2017

issue

5

1 reference

11 September 2017

page(s)

1369-1377

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-011-1813-7

11 September 2017

exact match

0 references

cites work

Upstream and downstream of mTOR

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1813-7

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1813-7

Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1813-7

Regulation of translation initiation by FRAP/mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1813-7

Mammalian target of rapamycin-dependent phosphorylation of PHAS-I in four (S/T)P sites detected by phospho-specific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1813-7

Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1813-7

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1813-7

Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1813-7

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1813-7

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1813-7

Pim family kinases enhance tumor growth of prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1813-7

Targeting the mTOR signaling network for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1813-7

Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1813-7

Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1813-7

Targeting the mTOR pathway using deforolimus in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1813-7

A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1813-7

Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1813-7

Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1813-7

10.1007/S00280-011-1813-7

21 January 2018

Identifiers

DOI

1 reference

release_bymp75fqd5gyvbxitxenwavozu

11 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bymp75fqd5gyvbxitxenwavozu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference